Pamlab, LLC, has launched Palgic[R], a new prescription antihistamine featuring carbinoxamine maleate.
In a placebo-controlled study involving 296 patients, carbinoxamine maleate 4 mg (Palgic) was found to be an effective single-agent antihistamine with a low side-effect profile.
of carbinoxamine maleate
(an antihistamine) and 25 mg.
Carbinoxamine Maleate 4mg Tablet is indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and food, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after acute manifestations have been controlled and amelioration of the severity of allergic reactions to blood or plasma.
Carbinoxamine Maleate 4mg Tablet is one more approval stemming from strong R&D and a robust product pipeline.
Oral Solution 4mg/5mL is indicated to treat seasonal and perennial allergic rhinitis.
The Histex(TM) acquisition consists of five cough, cold and allergy products; Histex(TM) Liquid (Clorpheniramine Maleate, Psuedoephedrine HCL), an antihistamine/decongestant, Histex(TM) HC Liquid CIII (Hydrocodone Bitartrate, Carbinoxamine Maleate
, Pseudoephedrine HCL), a cough suppressant/antihistamine/decongestant, Histex(TM) PD Liquid (Carbinoxamine Maleate
) an antihistamine, Histex(TM) CT Tablets (Carbinoxamine Maleate
) an antihistamine, Histex(TM) SR Capsules (Brompheniramine Maleate, Pseudoephedrine HCL) a antihistamine/decongestant.